Investigating the role of Th17 cells in chronic lymphocytic leukemia
Official title: Th17 generation, action and therapeutic relevance in chronic lymphocytic leukemia
Funded at Feinstein Institute for Medical Research · NIH-10735876 · Data updated 2026-11-12
This study is looking at how a special type of immune cell called Th17 cells interacts with cancer cells in chronic lymphocytic leukemia (CLL) to find new ways to help improve treatment for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Feinstein Institute for Medical Research NIH-funded |
| Lab location | 1 site (Manhasset, United States) |
| Project start | December 1, 2019 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $523,308 |
| NIH project number | 5R01CA238523-05 |
| Project ID | NIH-10735876 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic lymphocytic leukemia who are willing to participate in studies involving their immune cells.
✕Less likely to help
Patients with other types of blood cancers or those who do not have chronic lymphocytic leukemia may not benefit from this research.
What this research studies
This research focuses on understanding how a specific type of immune cell, known as Th17 cells, interacts with cancer cells in chronic lymphocytic leukemia (CLL). The study examines how these Th17 cells are generated and how they influence the survival and growth of CLL B cells. By analyzing the communication between these immune cells and cancer cells, the research aims to identify potential therapeutic strategies that could improve patient outcomes. Patients may be involved in providing samples to help explore these cellular interactions and their implications for treatment.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the immune response against chronic lymphocytic leukemia.
How similar studies have gone: Previous research has shown promising results in understanding the role of immune cells in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Feinstein Institute for Medical Research
Manhasset, United States Active
Researchers
- Principal investigator: Chiorazzi, Nicholas — Feinstein Institute for Medical Research
- Study coordinator: Chiorazzi, Nicholas
Related research
Other NIH-funded projects on the same topics.
-
Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome
A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.
-
Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults
A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.
-
AVO: a new triplet therapy for untreated high-risk CLL
A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.
-
Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia
A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.
-
METTL3's role in driving a stubborn form of chronic lymphocytic leukemia
A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.
-
Understanding why BTK inhibitors stop working in chronic lymphocytic leukemia
Researchers are studying why some people with chronic lymphocytic leukemia stop benefiting from BTK inhibitors and how to overcome that resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.